Global Bioenergies

The Isobutene process: short term opportunity and long term potential

October 2020



Listed on Euronext Growth: ALGBE Eligible to SRI investments This presentation contains certain forward-looking statements that have been based on current expectations about future acts, events and circumstances. These forward-looking statements are, however, subject to risks, uncertainties and assumptions that could cause those acts, events and circumstances to differ materially from the expectations described in such forward-looking statements.

These factors include, among other things, commercial, technical and other risks e.g. associated with estimation of the price of carbohydrate resources, the meeting of development objectives and other investment considerations, as well as other matters not yet known to the Company or not currently considered material by the Company.

Global Bioenergies accepts no responsibility to update any person regarding any error or omission or change in the information in this presentation or any other information made available to a person or any obligation to furnish the person with further information.







We prepare a more socially and environmentally responsible world for the next generation







We have developed a unique, innovative process to convert renewable resources into isobutene, a platform molecule widely used in cosmetics and also offering a clear opportunity for renewable jet fuel



Why Isobutene?

• On the short term, with oil price < \$120/bbl, renewable products are more expensive than their oil-based equivalents.

 \rightarrow Need to target markets where bio-based products are sold with a high price premium


 \rightarrow Isobutene is <u>THE</u> molecule with the largest high-premium market: tens of thousand tons in the cosmetics

• On the longer term, with a higher oil price and/or increasing commitments from States to preserve the environment, bio-based isobutene could become core for sustainable air transportation.



Unique Science and strong IP

 We have engineered bacteria to convert renewable resources into isobutene, a gaseous 4-carbon building-block molecule traditionally derived from fossil oil (>15 million tons per year)




- No biological starting point because Isobutene is not produced in Nature → We created an <u>artificial</u> metabolic pathway, first ever. Huge technology barrier overcome.
- First ever <u>fermentation process to a gas</u>. Brings key benefits: abrogation of productto-strain toxicity and simple purification scheme.
- Metabolic and chemical engineering breakthroughs covered by an IP fortress surrounding a know-how citadel.




The technology is now mature

2018-2019: Major breakthroughs achieved at lab-scale on yield and productivity



GLOBAL BIOENERGIES

Two main opportunities





Cosmetics

- Isobutene derivatives have an existing market in the cosmetics of ~30,000 tons/yr
- Current main emollient for cosmetics is being phased out
- Isobutene derivatives substitute with comparable level of performance
- Cosmetic companies are looking for bio-based compounds to increase their level of naturality
- Collaboration with L'ORÉAL since 2016
- Market for isobutene derivatives in the cosmetics expected to exceed 100,000 tons/year within a few years



Sustainable Jet Fuel

- Jet fuel is the most dynamic segment of the oil industry: +5% per year
- Market of 250 million tons fuel per year almost entirely based on fossil oil
- Only 4 different technologies provide biofuel batches for demonstration flights
- Norway has introduced a 0.5% mandate for Sustainable Aviation Fuel by 2020
- Air shame spreading \rightarrow need for action
- France and Europe are moving on regulatory
- Massive tax incentives soon expected
- Regulatory process ongoing in fast-track mode






Moving to commercial scale exploitation

IBN-One, a Joint-Venture with sugar player Cristal Union, has the project to finance, build and operate the first plant




↓Global Bioenergies



12

Diversifying the feedstocks to reach lower costs and further improve environmental impact



- €5.7m directly to GBE / €4.6m already received

- €3.3m to IBN-One / €1m already received (accounted at 50% in consolidation).

- The rest will be received based on expenses + financial and technical milestones

€9.3m already received by GBE. The rest will be received based on expenses and technical milestones



Executive summary

- 1. A unique Science, based on an innovative Synthetic Biology approach. Strong IP position.
- 2. The technology is at late development stage: High performances reached. Scale-up in progress.
- 3. Business in the cosmetics accessible on the short term.
- 4. One of the rare technologies having a potential for sustainable jet fuel

Executive committee

A seasoned management team...



Marc Delcourt Chief Executive Officer



Macha Anissimova Chief Scientific Officer



Samuel Dubruque Chief Financial Officer



Bernard Chaud Head of Industrial Strategy



Frédéric Ollivier Chief Technical Officer



Alexandra Ramirez-Moncada Chief Legal Officer



Dr. Richard E. Bockrath VP Chemical engineering Former Technical Director at DuPont




Dr. Charles E. Nakamura VP Metabolic engineering

25 years at DuPont. Received ACS award in 2007

Vice Presidents



Equity



En gris figurent les actionnaires présents au Conseil d'administration (BOLD en tant que censeur)



